Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 112.5K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Gillian D Sanders, Peter J. Neumann, Anirban Basu et al. · JAMA · 2016 · 3K citations · Full text

Pharmacy, Health Administration, Health Policy +17

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

Patricia Guyot, A. E. Ades, Mario JNM Ouwens et al. · BMC Medical Research Methodology · 2012 · 2.5K citations · Full text

Public Health, Biostatistics, Clinical Epidemiology +16

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein · New England Journal of Medicine · 2014 · 2.3K citations

Pharmacy, Health Policy, Pharmacoeconomics +17

Improved Survival with Bevacizumab in Advanced Cervical Cancer

Krishnansu S. Tewari, Michael W. Sill, Harry J. Long et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +15